Group 6 Copy 80
0
    Please wait...

    About This Project

    OncoSynergy, Inc.
    The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
    Blast off!

    Browse Other Projects on Experiment

    Related Projects

    CRISPR Capsules: Packaging Cas9 with bacterial outer membrane vesicles

    NU iGEM is creating a delivery system for an innovative antibiotic method centered around CRISPR, a powerful...

    Conserving California Red-Legged Frogs

    "My goal is to help protect California's natural legacy in an increasingly modified landscape, with the...

    Does insecticide exposure affect solitary bee nesting behavior?

    Alfalfa leafcutter bees (ALBs) are important crop pollinators that nest in aboveground cavities (e.g. straws...

    Backer Badge Funded

    A biology project funded by 47 people